GlassScriptPhysician profile
Philip T Chen
NPI 1073796728
$6,775.97
in general payments reported to CMS, 2019-2025
30 companies · $647 in 2025
The $647 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,223 · 2020: $636 · 2021: $1,623 · 2022: $1,143 · 2023: $410 · 2024: $1,093 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,089 · Education: $61.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,088.95 |
| Education | $61.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,603.13 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $1,566.43 | 2019-2024 | Rinvoq, Skyrizi, Creon |
| Takeda Pharmaceuticals U.S.A., INC. | $639.59 | 2019-2025 | Entyvio, Gattex |
| Allergan, INC. | $354.33 | 2019-2020 | |
| Madrigal Pharmaceuticals | $290.45 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $283.14 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Phathom Pharmaceuticals, INC. | $277.22 | 2024-2025 | Voquezna |
| Genzyme Corporation | $274.95 | 2022-2025 | |
| Qol Medical, LLC | $274.41 | 2019-2024 | Sucraid |
| Ironwood Pharmaceuticals, INC | $167.58 | 2022-2024 | Linzess |
| Exact Sciences Corporation | $124.51 | 2024 | |
| Nestle Healthcare Nutrition INC. | $118.67 | 2020-2021 | |
| Celgene Corporation | $117.27 | 2021-2022 | |
| Boston Scientific Corporation | $94.77 | 2021-2023 | Wavewriter Alpha Prime 16 |
| Daiichi Sankyo INC. | $92.04 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $86.53 | 2020-2022 | |
| Ardelyx, INC. | $77.09 | 2024-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $65.07 | 2020 | |
| Celltrion USA INC. | $40.33 | 2024-2025 | Zymfentra, Vegzelma |
| Ipsen Biopharmaceuticals, INC | $33.86 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $30.58 | 2019-2021 | |
| Shionogi INC | $23.67 | 2019 | |
| Alfasigma USA, INC. | $22.43 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $22.16 | 2023 | Dupixent |
| Ferring Pharmaceuticals INC. | $21.43 | 2019 | |
| Erbe USA INC | $20.40 | 2019 | |
| Cook Medical LLC | $18.43 | 2019 | |
| Gilead Sciences, INC. | $15.07 | 2019 | |
| Endogastric Solutions, INC | $11.84 | 2021 | |
| Intra-Sana Laboratories | $8.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.